Cogent Biosciences (COGT) Depreciation & Amortization (CF) (2017 - 2026)
Cogent Biosciences' (COGT) quarterly Depreciation & Amortization (CF) came in at $626000.0 in Q1 2026, down 2.19% year-on-year from $640000.0 in Q1 2025, and down 5.72% on a QoQ basis from $664000.0 in Q4 2025.
Cogent Biosciences (COGT) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $626000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 2.19% year-over-year to $626000.0 in Q1 2026; TTM through Mar 2026 was $2.6 million, a 1.77% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 4.0% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $626000.0, down from $664000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for COGT reached as high as $675000.0 in Q4 2024 and fell as low as $69000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $519176.5 across 5 years, with a median of $606000.0 in 2024.
- Across the five-year window, Depreciation & Amortization (CF) surged 666.67% in 2023 and fell 2.19% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $378000.0 in 2022, then jumped by 66.14% to $628000.0 in 2023, then advanced by 7.48% to $675000.0 in 2024, then fell by 1.63% to $664000.0 in 2025, then decreased by 5.72% to $626000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $626000.0 in Q1 2026, $664000.0 in Q4 2025, and $641000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Cogent Biosciences | 6.45 Bn | 6.45 Bn | - | 626,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 626,000.00 |
| Mar 31, 2026 | 626,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Sep 30, 2025 | 641,000.00 |
| Sep 30, 2025 | 641,000.00 |
| Jun 30, 2025 | 655,000.00 |
| Jun 30, 2025 | 655,000.00 |
| Mar 31, 2025 | 640,000.00 |
| Mar 31, 2025 | 640,000.00 |
| Dec 31, 2024 | 675,000.00 |
| Dec 31, 2024 | 675,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Jun 30, 2024 | 606,000.00 |
| Jun 30, 2024 | 606,000.00 |
| Mar 31, 2024 | 599,000.00 |
| Mar 31, 2024 | 599,000.00 |
| Dec 31, 2023 | 628,000.00 |
| Dec 31, 2023 | 628,000.00 |